pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2010-4-99-103pulmo-1678Research ArticleСтатьиХроническая обструктивная болезнь легких:
фармакоэкономические аспектыАрхиповВ. В.noemail@neicon.ruМосковская медицинская академия им. И.М.Сеченова, кафедра клинической фармакологииRussian Federation2010280820100499103Copyright © Архипов В.В., 20102010Архипов В.В.Архипов В.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1678хроническая обструктивная болезнь легкихтиотропия бромидбремя болезниэкономическая эффективностькачество жизниReferencesСоциально-экономическое бремя бронхиальной аст мы и хронической обструктивной болезни легких в Российской Федерации. РБОФ "Качество жизни", НИИ КЭФФ, М.: 2009.Социально-экономическое бремя бронхиальной аст мы и хронической обструктивной болезни легких в Российской Федерации. РБОФ "Качество жизни", НИИ КЭФФ, М.: 2009.Global strategy for the diagnosis, management, and preven tion of chronic obstructive pulmonary disease: GOLD exec utive summary. Am. J. Respir. Crit. Care Med. 2007; 176 (6): 532-555.Global strategy for the diagnosis, management, and preven tion of chronic obstructive pulmonary disease: GOLD exec utive summary. Am. J. Respir. Crit. Care Med. 2007; 176 (6): 532-555.Halpin D.M.G. Health economics of chronic obstructive pul monary disease. Proc. Am. Thorac. Soc. 2006; 3: 227-233.Halpin D.M.G. Health economics of chronic obstructive pul monary disease. Proc. Am. Thorac. Soc. 2006; 3: 227-233.Connors A.F., Dawson N.V., Thomas C. et al. Outcomes fol lowing acute exacerbation of severe chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 1996; 154: 959-967.Connors A.F., Dawson N.V., Thomas C. et al. Outcomes fol lowing acute exacerbation of severe chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 1996; 154: 959-967.Tashkin D., Celli B., Senn S. et al. A 4!year trial of tiotropi um in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543-1554.Tashkin D., Celli B., Senn S. et al. A 4!year trial of tiotropi um in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543-1554.Casaburi R., Mahler D.A., Jones P.W. et al. A long-term eval uation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.Casaburi R., Mahler D.A., Jones P.W. et al. A long-term eval uation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27: 547-555.Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27: 547-555.Calverley P.M., Anderson J.A., Celli B. et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137 (1): 20-30.Calverley P.M., Anderson J.A., Celli B. et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137 (1): 20-30.Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstruc tive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775-789.Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstruc tive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775-789.Rodrigo G.J., Castro1Rodrнguez J. A., Nannini L. J. et al. Safety and efficacy of combined long!acting beta-agonists and inhaled corticosteroids vs long!acting beta-agonists monotherapy for stable COPD: A systematic review. Chest 2009; 136 (3): 1029-1038.Rodrigo G.J., Castro1Rodrнguez J. A., Nannini L. J. et al. Safety and efficacy of combined long!acting beta-agonists and inhaled corticosteroids vs long!acting beta-agonists monotherapy for stable COPD: A systematic review. Chest 2009; 136 (3): 1029-1038.Бергер М.Л., Бингефорс К., Хедблом Э.С. и др. (ред.) Смит М. Д. (отв. ред.). Затраты, качество и результаты в здравоохранении: книга терминов ISPOR: Пер. с англ. М.: Ньюдиамед; 2009.Бергер М.Л., Бингефорс К., Хедблом Э.С. и др. (ред.) Смит М. Д. (отв. ред.). Затраты, качество и результаты в здравоохранении: книга терминов ISPOR: Пер. с англ. М.: Ньюдиамед; 2009.Global Initiative for Chronic Obstructive Lung Disease Web site. Pocket Guide to COPD Diagnosis, Management, and Prevention. A Guide for Health Care Professionals. Updated 2007. National Heart, Lung, and Blood Institute, National Institutes of Health. Available at: http://www.gold1 copd.com. Accessed February 12, 2008.Global Initiative for Chronic Obstructive Lung Disease Web site. Pocket Guide to COPD Diagnosis, Management, and Prevention. A Guide for Health Care Professionals. Updated 2007. National Heart, Lung, and Blood Institute, National Institutes of Health. Available at: http://www.gold1 copd.com. Accessed February 12, 2008.Morbidity and mortality: 2002 chart book on cardiovascular, lung and blood diseases. NIH / NHLBI. May 2002. 17.Morbidity and mortality: 2002 chart book on cardiovascular, lung and blood diseases. NIH / NHLBI. May 2002. 17.Jansson S.A., Andersson F., Borg S. et al. Costs of COPD in Sweden according to disease severity. Chest 2002; 122 (6): 1994-2002.Jansson S.A., Andersson F., Borg S. et al. Costs of COPD in Sweden according to disease severity. Chest 2002; 122 (6): 1994-2002.Gani R., Griffin J., Kelly S. et al. Economic analyses com paring tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim. Care Respir. J. 2010; 19 (1): 68-74.Gani R., Griffin J., Kelly S. et al. Economic analyses com paring tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim. Care Respir. J. 2010; 19 (1): 68-74.Naik Sh., Kamal Kh.M., Keys P.A., Mattei T.J. Evaluating the cost!effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. ClinicoEconom. Outcomes Res. 2010; 2: 25-36.Naik Sh., Kamal Kh.M., Keys P.A., Mattei T.J. Evaluating the cost!effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. ClinicoEconom. Outcomes Res. 2010; 2: 25-36.Tashkin D.P., Cooper C.B. The role of longacting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-259.Tashkin D.P., Cooper C.B. The role of longacting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-259.Friedman M., Menjoge Sh., Anton S.F., Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). ParmacoEconom. 2004; 22 (11): 741-749.Friedman M., Menjoge Sh., Anton S.F., Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). ParmacoEconom. 2004; 22 (11): 741-749.Oostenbrink J.B., Rutten van Molken M.P.M.H., Al M.J. et al. One year cost!effectiveness of tiotropium versus ipratropi um to treat COPD. Eur. Respir. J. 2004; 23: 241-249.Oostenbrink J.B., Rutten van Molken M.P.M.H., Al M.J. et al. One year cost!effectiveness of tiotropium versus ipratropi um to treat COPD. Eur. Respir. J. 2004; 23: 241-249.Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotro pium in combination with placebo, salmeterol, or fluticas one salmeterol for treatment of chronic obstructive pul monary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotro pium in combination with placebo, salmeterol, or fluticas one salmeterol for treatment of chronic obstructive pul monary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.Welte T. Miravitlles M., Peterson S. et al. Budesonide / formoterol added to tiotropium improves the management of COPD patients. Am. J. Respir. Crit. Care Med. 2009; 179: A6192.Welte T. Miravitlles M., Peterson S. et al. Budesonide / formoterol added to tiotropium improves the management of COPD patients. Am. J. Respir. Crit. Care Med. 2009; 179: A6192.Najafzadeh M., Marra C.A., Sadatsafavi M. et al. Cost effec tiveness of therapy with combinations of long acting bron chodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63: 962-967.Najafzadeh M., Marra C.A., Sadatsafavi M. et al. Cost effec tiveness of therapy with combinations of long acting bron chodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63: 962-967.Oba Y. Cost!effectiveness of longacting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin. Proc. 2007; 82 (5): 575-582.Oba Y. Cost!effectiveness of longacting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin. Proc. 2007; 82 (5): 575-582.Архипов В.В. Фармакоэкономический подход к тера пии хронической обструктивной болезни легких. Consilium Medicum 2006; 12 (3):16-19.Архипов В.В. Фармакоэкономический подход к тера пии хронической обструктивной болезни легких. Consilium Medicum 2006; 12 (3):16-19.Павленко С.С., Павленко Н.С., Куделя Л.М. и др. Иссле дование эффективности лечения больных хроничес кой обструктивной болезнью легких препаратом Спирива (тиотропия бромид) в Новосибирской области. Пульмонология 2005; 4: 92-96.Павленко С.С., Павленко Н.С., Куделя Л.М. и др. Иссле дование эффективности лечения больных хроничес кой обструктивной болезнью легких препаратом Спирива (тиотропия бромид) в Новосибирской области. Пульмонология 2005; 4: 92-96.
The authors declare that there are no conflicts of interest present.